<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079871</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-09-65</org_study_id>
    <nct_id>NCT01079871</nct_id>
  </id_info>
  <brief_title>Evaluation of FID 114657 in Sjogren's Syndrome Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the overall Sjogren's Syndrome subject's
      preference for a particular product. Dry eye symptom relief will also be evaluated based on
      clinical evaluation and a set of subject questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preference based on subject's relief of dry eye</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>FID 114657 (ORB Preserved Ocular Emulsion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FID 114657 (ORB Preserved Ocular Emulsion)</intervention_name>
    <description>Patients will dose as needed throughout the day (PRN) for 4 weeks.</description>
    <arm_group_label>FID 114657 (ORB Preserved Ocular Emulsion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 18 years of age, must read and sign the informed consent
             form (ICF), and must agree to comply with the study requirements.

          -  Patients must have a best corrected visual acuity of 0.6 LogMar or better in each eye,
             must report having an ocular examination in the last two years and must be using
             topical ocular dry eye therapy (artificial tears or Restasis) at least 4 times per
             day.

          -  Patients must have been diagnosed with Sjogren's Syndrome (confirmed or consistent
             with the American-European Consensus Criteria 2002).

        Exclusion Criteria:

          -  Patients cannot wear contact lenses within one week prior to visit 1 and cannot wear
             their contact lenses during the study.

          -  Patients cannot have a history of hypersensitivity to any component of FID 114657, and
             cannot have diabetes (Type 1 or 2).

          -  Patients cannot have ocular or intraocular surgery or serious ocular trauma within the
             past 6 months, and cannot have an eyelid abnormality that might affect lid function.

          -  Patients cannot have punctal plugs that were placed less than or equal to 30 days
             prior to Visit 1, and cannot have active infections or inflammations not associated
             with Sjogren's Syndrome.

          -  They cannot have started or changed the dose of chronic systemic medication within 7
             days prior to visit 1, and must remain on a stable dosing regimen for the duration of
             the study.

          -  Patients cannot have participated in another investigational clinical or research
             study within 30 days of visit 1 and are not allowed to participate in any other drug
             or device clinical trial for the duration of this study.

          -  Patients cannot have any findings in the vitreous, retina, macula and choroid that
             show signs of active inflammation and/or any structural change that in the opinion of
             the investigator is considered abnormal or unstable for that participant and/or a
             score of greater than 0 for the optic nerve.

          -  Patients can not have had punctal cauterization within 30 days prior to Visit 1, have
             a history of undergoing prior cataract surgery with complications as a result of the
             cataract surgery.

          -  Participants who have undergone prior cataract surgery without complications must be
             at least six months post-op with a stable refractive error.

          -  Patients cannot have received ocular prescription therapy in the last 30 days
             (Restasis can be used as long as stable for at least 30 days).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjogren's Syndrome</keyword>
  <keyword>Dry Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

